Key Takeaways
- Evotec has eliminated approximately 600 jobs, exceeding its initial target by 200 positions.
- The company’s revenues decreased by 5%, with a significant drop in discovery and preclinical development revenue.
- Evotec continues to streamline operations, recently selling a biologics facility and focusing on sustainable growth.
Job Cuts and Financial Performance
Evotec’s restructuring has led to the elimination of about 600 jobs since March 2024, surpassing the initially planned reduction of 400 roles. This decision follows CEO Christian Wojczewski’s emphasis on the need for the company to transform for sustainable, profitable growth. According to Wojczewski, the focus is on enhancing strengths, driving productivity, and reducing complexity to prepare for a new growth phase.
The company aims for annual savings exceeding 40 million euros (about $44 million). Recent reports indicate that the sales of the company fell by 5% during the first half of 2024, generating revenues of 371 million euros compared to 391 million euros in the previous year. A notable decline of 11% in revenues from the discovery and preclinical development (D&PD) division was attributed to a sustained decrease in demand.
Strategic Focus Shift
In contrast, Evotec’s contract development and manufacturing organization (CDMO) unit, Just – Evotec Biologics (JEB), performed well, reporting 16% year-over-year revenue growth in the same period. JEB is advancing towards an asset-lighter business model and concentrating on its core competencies. Efforts include the recent sale of its biologics manufacturing facility in Toulouse, France, to Sandoz, a partner in developing biosimilars. This strategic move aims to enhance the company’s revenue mix, profit margins, and capital efficiency.
The company’s performance in D&PD signals a need for further adjustment, as Evotec’s progress in strategic execution continues. Wojczewski stated that the organization is making “meaningful strides toward sustainable and profitable growth.”
Furthermore, in April 2024, Evotec cut roughly 30% of its asset portfolio and disposed of a phase 2 development candidate, marking an end to the company’s involvement in clinical development. The focus has now narrowed sharply, moving from target identification to investigative new drug (IND) applications, reflecting a significant shift in strategy.
Despite the job losses and revenue declines, Evotec maintains a global workforce of more than 5,000 employees. The ongoing transition reflects the company’s commitment to establishing a stronger foundation for future growth in the evolving biopharma landscape.
The content above is a summary. For more details, see the source article.